Aslan Fred sold $690K of ARTV

Aslan Fred (Chief Executive Officer) sold 61,888 shares of Artiva Biotherapeutics, Inc. (ARTV) at $11.16 ($0.69M total) on 2026-09-03.

Original reporting
SEC EDGAR · Aslan Fred
Published Sep 4, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
medium confidence
Mentioned
$ARTV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The Form 4 filing provides the first public disclosure of the CEO's recent share sale, offering fresh data for valuation models.

02

Market read

Insider transaction adds new information for traders monitoring ARTV, but the modest size limits broader market relevance.

03

What to watch

The CEO retains a large stake and the company may be preparing for upcoming clinical milestones.

Relevance 5/10Novelty 5/10Timing: same-day filing

Background

Artiva Biotherapeutics (ARTV) is a Nasdaq‑listed biotech developing therapies for liver diseases.

Company-level read

Ticker impact

$ARTVNeutralMedium confidence
Context

CEO Aslan Fred sold 61,888 shares for $690,391, reducing his stake to 1,473,194 shares.

Expected impact

Potential short‑term pressure on ARTV price, likely limited to a few percent.

Evidence & confidence

The sale represents less than 5% of the insider's total holdings and is under $1M, so market reaction is expected to be muted.

Market effects

Minimal impact on the broader biotech sector; similar insider sales are common.

No significant regional effect.

Limited to investors tracking ARTV.

Counterpoint

The sale could be a routine liquidity move rather than a negative signal.

Key entities

  • Artiva Biotherapeutics, Inc.

    Biotech firm developing liver disease treatments.

  • Aslan Fred

    Chief Executive Officer of Artiva Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.